Neurocrine Biosciences, Inc.  

(Public, NASDAQ:NBIX)   Watch this stock  
Find more results for NBIX
43.28
-1.31 (-2.94%)
Jun 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 41.56 - 44.71
52 week 31.25 - 58.46
Open 42.20
Vol / Avg. 8.93M/1.40M
Mkt cap 3.64B
P/E     -
Div/yield     -
EPS -1.24
Shares 86.66M
Beta 0.67
Inst. own 104%
Jul 27, 2016
Q2 2016 Neurocrine Biosciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 8, 2016
Neurocrine Biosciences Inc at Jefferies Healthcare Conference
May 27, 2016
Neurocrine Biosciences Inc Annual Shareholders Meeting (Estimated)
May 20, 2016
Neurocrine Biosciences Inc Annual Shareholders Meeting
May 12, 2016
Neurocrine Biosciences Inc at Bank of America Merrill Lynch Health Care Conference
May 5, 2016
Q1 2016 Neurocrine Biosciences Inc Earnings Call - Webcast
May 5, 2016
Q1 2016 Neurocrine Biosciences Inc Earnings Release
May 4, 2016
Neurocrine Biosciences Inc at Deutsche Bank Health Care Conference - Webcast
Apr 13, 2016
Neurocrine Biosciences Inc at Needham Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -128.43% -449.84%
Operating margin -139.05% -476.51%
EBITD margin - -471.41%
Return on average assets -16.54% -24.78%
Return on average equity -18.45% -28.09%
Employees 120 -
CDP Score - -

Address

12780 El Camino Real
SAN DIEGO, CA 92130-2042
United States - Map
+1-858-6177600 (Phone)
+1-858-6177602 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company's two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature.

Officers and directors

William H. Rastetter Ph.D. Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Kevin C. Gorman Ph.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Timothy P. Coughlin CPA Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Bill Aurora Vice President - Medical Affairs
Bio & Compensation  - Reuters
Eric S. Benevich Chief Commercial Officer
Bio & Compensation  - Reuters
Haig P. Bozigian Ph.D. Chief Development Officer
Age: 57
Bio & Compensation  - Reuters
Dimitri E. Grigoriadis Ph.D. Chief Research Officer
Age: 57
Bio & Compensation  - Reuters
Darin M. Lippoldt Chief Legal Officer
Age: 49
Bio & Compensation  - Reuters
Malcolm Lloyd-Smith Chief Regulatory Officer
Age: 58
Bio & Compensation  - Reuters
Christopher F. O'Brien M.D. Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters